Please wait a minute...

中国生物工程杂志

China Biotechnology
China Biotechnology  2020, Vol. 40 Issue (5): 22-29    DOI: 10.13523/j.cb.1911035
    
Heterologous Expression, Purification and Aggregation Characterization of Tau Core Fragment 306-378
WEI Wei,CHANG Bao-gen,WANG Ying,LU Fu-ping(),LIU Fu-feng()
Key Laboratory of the Ministry of Education of Industrial Fermentation Microorganisms, Tianjin Key Laboratory of Industrial Microbiology, National Engineering Laboratory of Industrial Enzymes, School of Bioengineering, Tianjin University of Science and Technology, Tianjin 300457, China
Download: HTML   PDF(1135KB) HTML
Export: BibTeX | EndNote (RIS)      

Abstract  

Tau is one of the microtubule-associated proteins. Its physiological function is to promote microtubule assembly and maintain microtubule stability. The phosphorylated Tau easily aggregated and subsequently caused a series of tauopathies. Of them, Alzheimer's disease is a common type of tauopathies. Six subtypes of Tau are also found in human brain because of different mRNA splicing of the same gene. They are respectively composed of 352, 381, 383, 410, 412 and 441 residues. The molecular weight of the six subtypes is among 48-67kDa, the R1, R2, R3 and R4 are the microtubule binding domains, which can bind to microtubule and maintain microtubule stability. Compared with the full-length Tau, the truncated Tau isoforms, such as R1-R4, are more likely to aggregate and have stronger aggregation kinetics. For example, the microtubule binding domain of R3 and R4 and the following 10 amino acid at the C-terminal of R4 sequence are the core peptide of the paired helical fibrils (PHFs), which has been proven to drive Tau aggregation. And its fibrillary 3D structure was also identified using micro-electron diffraction of Cryo-electron microscope. Herein, the core fragment 306-378 (Tau306-378) of Tau was heterogeneously expressed in Escherichia coli, and the purified Tau306-378 was obtained by Ni+ chelated affinity chromatography. The final production yield was about 10.35mg/L. Then, the results of sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot proved that Tau306-378 was expressed successfully. Moreover, the matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) was further used to confirm the molecular weight of Tau306-378. It was proved that most of the Tau306-378 were in the form of monomers. In addition, a small portion of dimers were also found in the protein sample, which is caused by the formation of disulfide bond among two monomers. In order to explorethe effect of induction temperature on the production of the target protein, four different induction temperatures (16℃, 25℃, 30℃ and 37℃) were investigated. The results showed that the expression of Tau306-378 was the highest at 30℃, followed by 25℃ and 16℃. However, the expression of Tau306-378 was the lowest at 37℃. The optimal inducing condition of Tau306-378 were identified: inducing at 30℃ for 16-20h with 0.5mmol/L of isopropyl-β-D-thiogalactopyranoside. Finally, thioflavin T fluorescence staining experiments were performed to probe its fibrillogenesis. The results of thioflavin T fluorescence experiments showed that the trend of aggregation dynamics presents a typical S-shaped curve. That is, the recombinant Tau306-378 has good aggregation characteristics, which could be used to study the aggregation characteristics and toxicity of Tau in vitro, as well as in the screening of various inhibitors against Tau fibrillogenesis.



Key wordsAlzheimer's disease      Tau      Heterologous expression      Purification      Aggregation characteristics     
Received: 20 November 2019      Published: 02 June 2020
ZTFLH:  Q816  
Corresponding Authors: Fu-ping LU,Fu-feng LIU     E-mail: fplu302@mail.tust.edu.cn;fufengliu@tust.edu.cn
Cite this article:

WEI Wei,CHANG Bao-gen,WANG Ying,LU Fu-ping,LIU Fu-feng. Heterologous Expression, Purification and Aggregation Characterization of Tau Core Fragment 306-378. China Biotechnology, 2020, 40(5): 22-29.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.1911035     OR     https://manu60.magtech.com.cn/biotech/Y2020/V40/I5/22

Fig.1 The basic structural unit and their associated residues of human full-length Tau protein It contains N-terminal projection region, proline rich region, microtubule binding domain and C-terminal region. Two N-terminal parts were labeled N1 and N2 respectively, and four repeat segments of the microtubule binding domain were labeled R1-R4. The core of paired helical fibril (PHF) is the R3, R4 domain and 10 residues of R4 C-terminal, namely Tau306-378. Other regions are the fuzzy coat of PHF
Sequence type Sequence (5'-3')
Amino acids VQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTF
Gene CATATGGTGCAGATTGTGTATAAGCCGGTGGACCTGAGCAAAGTGACCAGCAAATGCGGCAGCCTGGGCAATATTCATCA
CAAACCGGGTGGTGGCCAGGTGGAAGTGAAAAGCGAGAAGCTGGACTTTAAGGATCGCGTGCAGAGCAAGATCGGCAGC
CTGGATAACATTACCCATGTGCCGGGCGGCGGCAATAAGAAAATTGAAACCCACAAACTGACCTTC
Table 1 Tau306-378 amino acids and gene sequences
Fig.2 Flow chart of Tau306-378 expression and purification
Primer name Primer sequence (5'-3')
Nde I-Tau306-378-F GGAATTCCATATGGTGCAGATTGTGTATAAGCC
Xho I-Tau306-378-R CCGCTCGAGTCAATGGTGATGATGGTGGT
Table 2 The primers for PCR
Fig.3 Construction of recombinant expression vector pET22b-Tau306-378 (a) Schematic diagram of recombinant expression vector pET22b-Tau306-378 (b) Colony PCR identification of E. coli JM109 transformants M: 1kb gene larder; 1-3: pET22b-Tau306-378 transformants; 4: JM109 wild type
Fig.4 Heterologous expression of Tau306-378 (a) Heterologous expression of Tau306-378 M: Protein marker; 1: Supernatant of BL21-pET22b; 2: Supernatant of BL21-pET22b-Tau306-378; 3: Pellets of BL21-pET22b-Tau306-378, Tau306-378 band in red box (b) Western blot analysis of Tau306-378 C: Supernatant of BL21-pET22b; 1: Supernatant of BL21-pET22b-Tau306-378; 2: Pellets of BL21-pET22b-Tau306-378
Fig.5 Optimization of Tau306-378 expression conditions and purification (a) Expression of Tau306-378 protein after induction at four different temperatures M: Protein marker; 1, 2: Induction at 16℃; Induction at 3, 4: Induction at 25℃; 5, 6: Induction at 30℃; 7, 8: Induction at 37℃; The loading buffers for the samples shown in lanes 1, 3, 5, and 7 were not treated with 2-ME, and the loading samples in lanes 2, 4, 6, and 8 were treated with normal loading buffer [ contains 5% (V /V) 2-ME] (b) The purification samples of protein at different stages after induction at 30℃ M: Protein marker; 1: Supernatant of BL21-pET22b; 2: Supernatant of BL21-pET22b-Tau306-378; 3: Flow through; 4: Protein solution eluted by wash buffer; 5:Protein solution eluted by elution buffer; 6: Pellets of BL21-pET22b; 7: Pellets of BL21-pET22b-Tau306-378
Fig.6 Identification and aggregation kinetics of Tau306-378 (a)MALDI-TOF mass spectrometry identification of Tau306-378 (b)Aggregation kinetics curve of Tau306-378
[1]   Fitzpatrick A, Falcon B, He S , et al. Cryo-EM structures of Tau filaments from Alzheimer's disease brain. Nature, 2017,547(7662):185-190.
[2]   Hardy J . Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. Journal of Alzheimers Disease, 2006,9(S3):151-153.
[3]   Rossor M N . Molecular pathology of Alzheimer's disease. Journal of Neurology Neurosurgery and Psychiatry, 1993,56(6):583-586.
[4]   Yankner B A, Duffy L K, Kirschner D A . Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science, 1990,250(4978):279-282.
[5]   Wang Y, Mandelkow E . Tau in physiology and pathology. Nature Reviews Neuroscience, 2016,17(1):5-21.
[6]   Liu F F, Dong X Y, He L Z , et al. Molecular insight into conformational transition of amyloid beta-peptide 42 inhibited by (-)-epigallocatechin-3-gallate probed by molecular simulations. Journal of Physical Chemistry B, 2011,115(41):11879-11887.
[7]   Kametani F, Hasegawa M . Reconsideration of amyloid hypothesis and Tau hypothesis in Alzheimer's disease. Frontiers in Neuroscience, 2018,12(25):1-11.
[8]   Brier M R, Gordon B, Friedrichsen K , et al. Tau and abeta imaging, CSF measures, and cognition in Alzheimer's disease. Science Translational Medicine, 2016,8(338):338ra366.
[9]   Shammas S L, Garcia G A, Kumar S , et al. A mechanistic model of Tau amyloid aggregation based on direct observation of oligomers. Nature Communications, 2015,6(1):1-10.
[10]   Mandelkow E M, Mandelkow E . Tau protein and Alzheimer's disease. Neurobiology of Aging, 1994,15(1):85-86.
[11]   Rademakers R, Cruts M, van Broeckhoven C . The role of tau (MAPT) in frontotemporal dementia and related tauopathies. Human Mutation, 2010,24(4):277-295.
[12]   Verwilst P, Kim H S, Kim S , et al. Shedding light on Tau protein aggregation: the progress in developing highly selective fluorophores. Chemical Society Reviews, 2018,47(7):2249-2265.
[13]   Seidler P M, Boyer D R, Rodriguez J A , et al. Structure-based inhibitors of Tau aggregation. Nature Chemistry, 2018,10(2):170-176.
[14]   Bratus S, Pak I . Structure, microtubule interactions, and paired helical filament aggregation by Tau mutants of frontotemporal dementias. Biochemistry, 2000,39(38):11714-11721.
doi: 10.1021/bi000850r
[15]   Hasegawa M, Smith M J, Goedert M . Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. Febs Letters, 1998,437(3):207-210.
[16]   Karikari T K, Turner A, Stass R , et al. Expression and purification of Tau protein and its frontotemporal dementia variants using a cleavable histidine tag. Protein Expression and Purification, 2016,130:44-54.
[17]   Michel C H, Kumar S, Pinotsi D , et al. Extracellular monomeric Tau protein is sufficient to initiate the spread of Tau protein pathology. Journal of Biological Chemistry, 2013,289(2):956-967.
doi: 10.1074/jbc.M113.515445
[18]   Yao T M, Tomoo K, Ishida T , et al. Aggregation analysis of the microtubule binding domain in Tau protein by spectroscopic methods. Journal of Biochemistry, 2003,134(1):91-99.
[19]   Barghorn S, Davies P, Mandelkow E . Tau paired helical filaments from Alzheimer's disease brain and assembled in vitro are based on β-structure in the core domain. Biochemistry, 2004,43(6):1694-1703.
[20]   Jia L G, Wang W J, Shang J Z , et al. Highly efficient soluble expression, purification and characterization of recombinant Aβ42 from Escherichia coli. Rsc Advances, 2018,8(33):18434-18441.
[21]   Du W J, Guo J J, Gao M T , et al. Brazilin inhibits amyloid β-protein fibrillogenesis, remodels amyloid fibrils and reduces amyloid cytotoxicity. Scientific Reports, 2015,5(1):1-10.
[22]   Jia L G, Wang W J, Sang J C , et al. Amyloidogenicity and cytotoxicity of a recombinant C-terminal His-Tagged Aβ. Acs Chemical Neuroscience, 2019,10(3):1251-1262.
[23]   Li S, Liu F F, Yu L L , et al. Dual effect of thioflavin T on the nucleation kinetics of amyloid β-protein 40. Acta Physico-Chemica Sinica, 2016,32(6):1391-1396.
[24]   Kundel F, De S, Flagmeier P , et al. Hsp70 inhibits the nucleation and elongation of Tau and sequesters Tau aggregates with high affinity. Acs Chemical Biology, 2018,13(3):636-646.
[1] ZHANG Ling,CAO Xiao-dan,YANG Hai-xu,LI Wen-lei. The Application of Continuous Purification in Affinity Chromatography and Evaluation of Production Scale-up[J]. China Biotechnology, 2021, 41(6): 38-44.
[2] RAO Hai-mi,LIANG Dong-mei,LI Wei-guo,QIAO Jian-jun,CAI YIN Qing-ge-le. Advances in Synthetic Biology of Fungal Aromatic Polyketides[J]. China Biotechnology, 2020, 40(9): 52-61.
[3] LV Yi-fan,LI Geng-dong,XUE Nan,LV Guo-liang,SHI Shao-hui,WANG Chun-sheng. Prokaryotic Expression, Purification of LbCpf1 Protein Gene and in Vitro Cleavage Activity Assay[J]. China Biotechnology, 2020, 40(8): 41-48.
[4] JIANG Dan-dan,WANG Yun-long,LI Yu-lin,Zhang Yi-qing. Study on the Delivery of RGD Modified Virus-Like Particles to ICG Targeted Tumors[J]. China Biotechnology, 2020, 40(7): 22-29.
[5] XIE Hang-hang,BAI Hong-mei,YE Chao,CHEN Yong-jun,YUAN Ming-cui,MA Yan-bing. The Purification Procedure for the Recombinant HBcAg Virus-like Particle Easy to Generate Aggregation[J]. China Biotechnology, 2020, 40(5): 40-47.
[6] LIU Zhen-zhen,TIAN Da-yong. Development of Sucrose Density Gradient Centrifugation Purification Process for Rabies Vaccine[J]. China Biotechnology, 2020, 40(4): 25-33.
[7] ZHU Tong-tong,YANG Lei,LIU Ying-bao,SUN Wen-xiu,ZHANG Xiu-guo. Purification and Crystallization of PcCRN20-C from Phytophthora capsici[J]. China Biotechnology, 2020, 40(1-2): 116-123.
[8] PAN Bing-jv,ZHANG Wan-yi,SHEN Hui-tao,LIU Ting-ting,LI Zhong-yuan,LUO Xue-gang,SONG Ya-jian. Research Progress on Separation and Purification of Mannan Oligosaccharide[J]. China Biotechnology, 2020, 40(11): 90-95.
[9] Yu-feng XIE,Xue-mei HAN,Fu-ping LU. Expression, Purification and Enzymatic Properties of β-glucosidase from Lactobacillus paracasei[J]. China Biotechnology, 2019, 39(5): 72-79.
[10] JING Jia-mei,XUN Xin,WANG Min,PENG Ru-chao,SHI Yi. Expression and Purification of C-terminal of Arenavirus Polymerase and Screening of Crystallization Conditions[J]. China Biotechnology, 2019, 39(12): 18-23.
[11] ZHU Meng-lu,WANG Xue-yu,LIU Xin,LU Fu-ping,SUN Deng-yue,QIN Hui-min. Heterologous Expression, Purification and Enzymatic Properties of a Novel Leucine 5-Hydroxylase[J]. China Biotechnology, 2019, 39(12): 24-34.
[12] SHI Chao-shuo,LI Deng-ke,CAO Xue,YUAN Hang,ZHANG Yu-wen,YU Jiang-yue,LU Fu-ping LI Yu. The Effect on Heterologous Expression of Alkaline Protease AprE by Two Different Promoter and Combinatorial[J]. China Biotechnology, 2019, 39(10): 17-23.
[13] CHEN Zi-han,ZHOU Hai-sheng,YIN Xin-jian,WU Jian-ping,YANG Li-rong. Optimizing the Culture Conditions for Amphibacillus xylanus Glutamate Dehydrogenase Gene Engineering Bacteria[J]. China Biotechnology, 2019, 39(10): 58-66.
[14] Chao-di TONG,Jian-ping WU,Li-rong YANG,Gang XU. Crystal Structural Analysis of DehDIV-R by X-ray Crystallography[J]. China Biotechnology, 2018, 38(8): 19-25.
[15] Jun-jun CHEN,Ying LOU,Yuan-xing ZHANG,Qin LIU,Xiao-hong LIU. Expression and Purification of Proliferating Cell Nuclear Antigen in Spodoptera frugiperda Cells[J]. China Biotechnology, 2018, 38(7): 14-20.